RA PHARMACEUTICALS INC's ticker is RARX and the CUSIP is 74933V108. A total of 151 filers reported holding RA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 16.18 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $15,344,000 | +0.8% | 319,579 | -1.5% | 0.00% | 0.0% |
| Q4 2019 | $15,225,000 | +3774.0% | 324,429 | +1851.9% | 0.00% | – |
| Q3 2019 | $393,000 | +90.8% | 16,621 | +141.8% | 0.00% | – |
| Q2 2019 | $206,000 | -91.1% | 6,873 | -93.4% | 0.00% | -100.0% |
| Q1 2019 | $2,326,000 | +472.9% | 103,858 | +365.5% | 0.00% | – |
| Q4 2018 | $406,000 | -13.6% | 22,312 | -14.2% | 0.00% | – |
| Q3 2018 | $470,000 | +48.7% | 26,012 | -18.1% | 0.00% | – |
| Q2 2018 | $316,000 | +65.4% | 31,753 | -11.8% | 0.00% | – |
| Q1 2018 | $191,000 | -7.7% | 36,002 | +48.2% | 0.00% | – |
| Q4 2017 | $207,000 | -5.9% | 24,300 | +61.6% | 0.00% | – |
| Q3 2017 | $220,000 | +7.3% | 15,041 | +37.6% | 0.00% | – |
| Q2 2017 | $205,000 | -55.6% | 10,932 | -49.6% | 0.00% | – |
| Q1 2017 | $462,000 | -36.4% | 21,672 | -54.6% | 0.00% | – |
| Q4 2016 | $726,000 | – | 47,756 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 6,138,797 | $294,724,000 | 15.40% |
| RA Capital Management | 4,858,260 | $233,245,000 | 7.37% |
| HAVENS ADVISORS LLC | 143,266 | $6,878,000 | 6.70% |
| BARDIN HILL MANAGEMENT PARTNERS LP | 609,614 | $29,267,000 | 6.40% |
| OMNI PARTNERS LLP | 1,052,744 | $50,542,000 | 4.45% |
| HBK INVESTMENTS L P | 2,004,042 | $96,214,000 | 4.03% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,005,600 | $96,289,000 | 3.83% |
| Versor Investments LP | 1,108,845 | $53,236,000 | 3.53% |
| OXFORD ASSET MANAGEMENT LLP | 461,016 | $22,133,000 | 3.12% |
| HighVista Strategies LLC | 63,222 | $3,035,000 | 2.81% |